DAIKEN MEDICAL CO.,LTD. (7775.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	10.2B	10.3B	10.0B	9.8B	9.1B
Cost of Revenue	1.5B	6.3B	5.9B	5.8B	5.6B
Gross Profit	955.5M	4.0B	4.1B	4.0B	3.5B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	673.7M	2.7B	2.6B	2.5B	2.5B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	673.7M	2.7B	2.6B	2.5B	2.5B
Cost and Expenses	8.9B	9.0B	8.4B	8.3B	8.1B
Operating Income (EBIT)	1.3B	1.3B	1.5B	1.4B	1.1B
Non-Operating
Interest Income	—	1.9M	—	—	—
Interest Expense	2.8M	12.3M	9.4M	4.8M	4.0M
Net Interest Income	—	(10.5M)	(9.4M)	(4.8M)	(4.0M)
Other Non-Op Income/Expense	204.0K	(3.2M)	(1.9M)	7.4M	(823.0K)
Non-Operating Income (excl Interest)	1.3M	7.3M	7.8M	12.2M	3.2M
EBT (Pre-Tax Income)	282.1M	1.2B	1.5B	1.4B	1.0B
Income Tax Expense	66.6M	323.5M	410.8M	447.9M	313.0M
Bottom Line
Net Income	980.0M	922.0M	1.1B	988.0M	712.0M
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	980.0M	922.0M	1.1B	988.0M	712.0M
Per Share
Basic EPS	¥34	¥32	¥38	¥34	¥25
Diluted EPS	¥34	¥32	—	—	—
Revenue Per Share	¥354	¥358	¥346	¥339	¥318
Shares
Basic Shares Outstanding	28.7M	28.7M	28.7M	28.7M	28.7M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	1.5B	1.7B	1.7B	1.3B
D&A	—	258.0M	232.6M	214.3M	267.3M
EBIT	1.3B	1.3B	1.5B	1.4B	1.1B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026